Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Nivolumab and ipilimumab combination receives FDA orphan drug designation

Oct. 16, 2014

Advaxis reports preliminary data from phase I/II trial of ADXS-HPV in anal cancer

Oct. 16, 2014

Phase I data for MPDL-3280A for the treatment of UBC and other malignancies

Oct. 15, 2014

GAPVAC consortium advances a personalized cancer vaccine approach into the clinic for glioblastoma

Oct. 15, 2014

FDA accepts BLA for blinatumomab in acute lymphoblastic leukemia

Oct. 10, 2014

RedoxTherapies licenses Vernalis' vipadenant for immuno-oncology applications

Oct. 9, 2014

FDA grants orphan drug status to DNX-2401 for glioma

Oct. 8, 2014

BMS and MD Anderson Cancer Center form immuno-oncology collaboration

Oct. 7, 2014

Sorrento Therapeutics outlicenses Chinese rights to anti-PD-L1 antibody

Oct. 7, 2014

Oxford BioTherapeutics and Berlin Chemie/Menarini select second anticancer antibody-drug conjugate

Oct. 6, 2014

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...